Galen acquires DaunoXome® (daunorubicin citrate liposome injection) for advanced HIV-associated Kaposi's sarcoma

Galen acquires DaunoXome® (daunorubicin citrate liposome injection) for advanced HIV-associated Kaposi's sarcoma

Souderton, Pennsylvania, February 23, 2012 /PRNewswire/ — Galen, a Northern Ireland Pharmaceutical company, has acquired the chemotherapy agent, DaunoXome® (daunorubicin citrate liposome injection) from Gilead Sciences, Inc. Galen US, Inc., a wholly owned subsidiary of Galen Ltd., will market DaunoXome® in the United States.

DaunoXome® is an anthracycline chemotherapy agent that was first approved in the United States in 1996. It is indicated as a first-line cytotoxic therapy for advanced HIV-associated Kaposi's sarcoma (KS)1 and has been shown to be as effective as a triple chemotherapy regimen in this disease.2 KS is a type of cancer that affects both the skin and organs inside the body, such as the lungs, liver, and digestive tract in patients living with active HIV.3,4

"HIV-associated KS is an AIDS-defining illness, which has considerable impact on patient prognosis. For some HIV patients with advanced or poorly controlled KS, chemotherapy may be required alongside highly active antiretroviral therapy, to effectively target the cancer. DaunoXome® provides a much needed option for physicians needing to treat advanced HIV-associated KS patients with such chemotherapy regimens," says Dr Anil Tulpule, Associate Professor of Medicine at the Norris Cancer Center, Los Angeles, California.

Galen is dedicated to supporting the development and provision of innovative medicines in an effort to improve health worldwide. Speaking about the acquisition of DaunoXome®, President of Galen, Mark Scrutton, commented: "We are delighted that we are now able to supply DaunoXome® in the United States for the treatment of patients with this devastating disease. DaunoXome® marks our first step into the oncology arena and this exciting, new acquisition provides us with the opportunity to offer more widely a much-needed therapy for patients with advanced HIV-associated KS."

For healthcare professionals who require further information about the product, including reimbursement, a dedicated helpline is available at 1-855-DAUNOXOME (1-855-328-669663). It is the healthcare professional's sole responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. Coverage, coding and reimbursement guidelines will vary according to individual insurance plans. Healthcare professionals should contact insurers to verify correct coding procedures prior to submitting claims related to DaunoXome®. In all cases, healthcare professionals will need to follow local payer policies for billing and reimbursement.

DaunoXome® will be made available through wholesalers in the United States.

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.